Like many medications, the effectiveness of retatrutide depends heavily on the correct dosage
Safety data is reviewed across multiple study phases before approval is considered
The safest path is one that involves medical guidance, realistic expectations, and long-term planning, not shortcuts
Since both retatrutide and tirzepatide are made by Eli Lilly, the transition should be straightforward
The growth of GLP-1 treatment within diabetes Glucagon-like peptide 1 (GLP-1) receptor agonists have taken the healthcare world by storm, becoming one of the most successful drug classes of all time, reaching an astonishing $110 billion in sales in 2024 alone 1
More specifically, they were originally designed for people with non-insulin dependent diabetes